RankAlpha logo
Back to Rankings

ENLV

EnlivexA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
RMAT designation and the planned Phase IIb program provide credible but early clinical optionality. Successful enrollment, efficacy confirmation, and regulatory alignment could support a substantial rerating; the proposed financing could also improve strategic flexibility.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite.
What can break
No verified Q2 2026 company earnings release, EPS or revenue surprise, guidance update, or earnings transcript was located in this T+3 review.
Momentum
87
Value
44
Sentiment
99
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.35 · Bull $2.20 · Bear $0.65Analysis 2026-09-01; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-01 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-09-10

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions

Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $80.00
Why
Momentum87 · Δ7d -
Value44 · Δ7d -0.0
Sentiment99 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • No verified Q2 2026 company earnings release, EPS or revenue surprise, guidance update, or earnings transcript was located in this T+3 review.
  • • Peer comparability and analyst coverage are weak, limiting confidence in relative valuation and target prices.
  • • This remains a very small, low-coverage biotech with limited verified forward financial information.

Catalyst clock

2026-07-13

FDA RMAT designation for Allocetra

Lead driver: Sentiment · See AI snapshot
Momentum
87
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
99
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 87.4 / Value 44.4 / Sentiment 98.6

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-01. Scenario method

B+
Bull case
20%
Probability
Target price
$2.20
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$1.35
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-01 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$26.6M
Beta
1.61
Shares Out
16.83M
P/E (TTM) · Derived
0.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.26
Rev YoY
-
EPS YoY
-11884.6%
Gross Margin
-
Op Margin
-
Net Debt
-$5.23M
Current Ratio
193.24
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data